Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).

NCT00714493 is registered in ClinicalTrials.gov with Centocor Ortho Biotech Services, L.L.C. as lead sponsor.

NCT NCT00714493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00714493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2008
Completion date
June 30, 2010
Enrollment
203 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis